Advertisement

Clinical Efficacy and Safety of Intravenous Tissue Plasminogen Activator in Acute Embolic Stroke: A Randomized, Double-Blind, Dose-Comparison Study of Duteplase

  • T. Yamaguchi
  • H. Kikuchi
  • T. Hayakawa
  • for the Japanese Thrombolysis Study Group

Abstract

Clinical evidence of favorable outcome in patients with spontaneous early reperfusion encouraged us to use a thrombolytic agent in hyperacute embolic stroke patients [1,2]. We have reported earlier the results of a placebo-controlled, double-blind trial of 20 million international units (MIU) of recombinant tissue plasminogen activator (rt-PA, duteplase) in hyperacute embolic stroke [3,4]. The study suggested that 20 MIU of intravenous rt-PA was safe and effective for treatment of acute embolic stroke, if it was applied within 6 h of onset in patients with arterial occlusions of the internal carotid axis and with no apparent hypodensity on computed tomographic (CT) scans.

Keywords

Middle Cerebral Artery Acute Ischemic Stroke Tissue Plasminogen Activator Arterial Occlusion Hemorrhagic Transformation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Minematsu K, Yamaguchi T, Omae T (1992) Spectacular shrinking deficit: rapid recovery from a major hemispheric syndrome by migration of an embolus. Neurology 42: 157–162PubMedGoogle Scholar
  2. 2.
    Yamaguchi T, Hayakawa T, Kikuchi H, Abe T (1991) Thrombolytic therapy in thrombotic and embolic cerebral infarction: a cooperative study. In: Hacke W, del Zoppo GJ, Hirschberg M (eds) Thrombolytic therapy in acute ischemic stroke. Springer, Berlin Heidelberg New York, pp 168–174CrossRefGoogle Scholar
  3. 3.
    Yamaguchi T, Hayakawa T, Kikuchi H, for the Japanese Thrombolysis Study Group (1993) Intravenous tissue plasminogen activator in acute thromboembolic stroke: a placebo-controlled, double-blind trial. In: del Zoppo GJ, Mori E, Hacke W (eds) Thrombolytic therapy in acute ischemic stroke, II. Springer, Berlin Heidelberg New York, pp 59–65CrossRefGoogle Scholar
  4. 4.
    Yamaguchi T, Hayakawa T, Kikuchi H, for the Japanese Thrombolysis Study Group (1993) Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis 3: 269–272CrossRefGoogle Scholar
  5. 5.
    Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A (1992) Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 42: 976–982PubMedGoogle Scholar
  6. 6.
    Von Kummer R, Hacke W (1992) Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 23: 646–652CrossRefGoogle Scholar
  7. 7.
    Adams RL, Meador KJ, Sethi KD, Grotta JC, Thompson DS (1987) Graded neurological scale for use in acute hemispheric stroke treatment protocols. Stroke 18: 665–669PubMedCrossRefGoogle Scholar
  8. 8.
    del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O. Greenlee RJ, Brass L, Mohr JP, Feldmann E, Hacke W, Kase CS, Biller J, Gress D, Otis SM (1992) Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 32: 78–86PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1995

Authors and Affiliations

  • T. Yamaguchi
    • 1
  • H. Kikuchi
    • 2
  • T. Hayakawa
    • 3
  • for the Japanese Thrombolysis Study Group
  1. 1.Cerebrovascular DivisionNational Cardiovascular CenterSuita City, Osaka, 565Japan
  2. 2.Department of Neurosurgery, Faculty of MedicineKyoto UniversitySakyo-ku, KyotoJapan
  3. 3.Department of NeurosurgeryOsaka University Medical SchoolSuita, Osaka, 565Japan

Personalised recommendations